Positive Phase 3 Data Could Net Verona Pharma a First-in-Class COPD Treatment
Nebulized ensifentrine, an investigational inhaled anti-inflammatory, reduced exacerbations of chronic obstructive pulmonary disease (COPD) by 42 percent over 24 weeks — a significant benefit that could propel Verona Pharma to…